Horizon Discovery Group plc, the world leader in the application of gene editing technologies, has announced the signing of a Master Services Agreement (MSA) with Top Three Global Pharmaceutical Company, extending support for their drug discovery and development efforts to Horizon’s full suite of services.

Adding to a pre-existing MSA for in vivo services, the terms of this agreement now cover a range of Horizon’s in vitro service offerings, defining the pricing and terms that will govern future transactions and facilitating simplified entry into forthcoming agreements. Services included under the MSA are: Custom cell line engineering, target identification and validation screening (including the use of CRISPR gene editing technology), drug combination screening, and cell-based assay services.

Horizon is establishing itself as a key provider to an increasing number of major pharmaceutical and biotech companies by delivering reliable, high-quality, high-value services, and by strengthening key relationships within each organisation.  In this way, Horizon was able to negotiate this agreement, building trust with the Company and becoming a preferred provider over time.  It is now Horizon’s single largest customer, contributing over £1.5 million in revenue in 2016 and the current project pipeline indicates there will be an expansion of revenue received in 2017.

Dr. Darrin Disley, Chief Executive Officer Horizon Discovery, commented: “Today’s announcement demonstrates the success of Horizon’s strategy of deepening relationships with our top customers. By taking a broader and more integrated approach, we are able to identify areas where we can provide significant value and are able to offer unified solutions that involve a range of Horizon’s services. In 2016, our top 20 customers provided over £9.8 million to the Group, and in 2017 we are looking to increase our revenue from this segment by at least 20%, with this agreement serving as a template.”